<table border="0" cellpadding="0" cellspacing="0" width="99%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5. Clinically-Significant Drug Interactions with Sertraline Hydrochloride 
			</caption>
<colgroup>
<col width="17.84%"></col>
<col width="82.16%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs) </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">The concomitant use of SSRIs including sertraline hydrochloride and MAOIs increases the risk of serotonin syndrome. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Sertraline hydrochloride is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue <content stylecode="italics">[See <linkhtml href="#Section_2.5">Dosage and Administration (2.5)</linkhtml>, <linkhtml href="#Section_4">Contraindications (4)</linkhtml>, <linkhtml href="#Section_5.2">Warnings and Precautions (5.2)</linkhtml>]. </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Pimozide </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Increased plasma concentrations of pimozide, a drug with a narrow therapeutic index, may increase the risk of QT prolongation and ventricular arrhythmias. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Concomitant use of pimozide and sertraline hydrochloride is contraindicated <content stylecode="italics">[See <linkhtml href="#Section_4">Contraindications (4)</linkhtml>]. </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Other Serotonergic Drugs </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">The concomitant use of serotonergic drugs with sertraline hydrochloride increases the risk of serotonin syndrome. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Monitor patients for signs and symptoms of serotonin syndrome, particularly during treatment initiation and dosage increases. If serotonin syndrome occurs, consider discontinuation of sertraline hydrochloride and/or concomitant serotonergic drugs <content stylecode="italics">[See <linkhtml href="#Section_5.2">Warnings and Precautions (5.2)</linkhtml>]. </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. Johnâ€™s Wort <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Drugs that Interfere with Hemostasis (antiplatelet agents and anticoagulants) </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">The concurrent use of an antiplatelet agent or anticoagulant with sertraline hydrochloride may potentiate the risk of bleeding. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Inform patients of the increased risk of bleeding associated with the concomitant use of sertraline hydrochloride and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio <content stylecode="italics">[See <linkhtml href="#Section_5.3">Warnings and Precautions (5.3)</linkhtml>]. </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">aspirin, clopidogrel, heparin, warfarin <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Drugs Highly Bound to Plasma Protein </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Sertraline hydrochloride is highly bound to plasma protein. The concomitant use of sertraline hydrochloride with another drug that is highly bound to plasma protein may increase free concentrations of sertraline hydrochloride or other tightly-bound drugs in plasma <content stylecode="italics">[See <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Monitor for adverse reactions and reduce dosage of sertraline hydrochloride or other protein-bound drugs as warranted. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples: </content>
<br/>
</td>
<td stylecode="Rrule" valign="middle">warfarin <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Drugs Metabolized by CYP2D6 </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Sertraline hydrochloride is a CYP2D6 inhibitor <content stylecode="italics">[See <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>. The concomitant use of sertraline hydrochloride with a CYP2D6 substrate may increase the exposure of the CYP2D6 substrate. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Decrease the dosage of a CYP2D6 substrate if needed with concomitant sertraline hydrochloride use. Conversely, an increase in dosage of a CYP2D6 substrate may be needed if sertraline hydrochloride is discontinued. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, thoridazine, tolterodine, venlafaxine <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Phenytoin </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Phenytoin is a narrow therapeutic index drug. Sertraline hydrochloride may increase phenytoin concentrations. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">Monitor phenytoin levels when initiating or titrating sertraline hydrochloride. Reduce phenytoin dosage if needed. <br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples: </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">phenytoin, fosphenytoin <br/>
</td>
</tr>
</tbody>
</table>